David Sallman, Monzr Al Malki, Adam Asch, Eunice Wang, Joseph Jurcic, Terrence Bradley, Ian Flinn, Daniel Pollyea, Suman Kambhampati, Tiffany Tanaka, Joshua Zeidner, Guillermo Garcia-Manero, Deepa Jeyakumar, Lin Gu, Anderson Tan, Mark Chao, Carol O'Hear, Indu Lal, Paresh Vyas, Naval Daver
CONTEXT: Magrolimab is a monoclonal antibody blocking CD47, a "don't eat me" signal overexpressed on cancer cells, which leads to tumor phagocytosis and is synergistic with azacitidine. A high unmet need exists to build on current standard-of-care azacitidine in patients with HR MDS. OBJECTIVE: Report final safety/tolerability and efficacy data. DESIGN: Ph1b trial of magrolimab+azacitidine (NCT03248479). PATIENTS: 95 patients with untreated HR MDS (intermediate, high, or very-high risk per the Revised International Prognostic Scoring System [IPSS-R])...
October 2022: Clinical Lymphoma, Myeloma & Leukemia